No Survival Benefit in CRPC With New Anti-Androgen

SAN FRANCISCO (MedPage Today) -- An investigational anti-androgen failed to improve overall survival in a randomized trial of men with docetaxel-treated metastatic castration-resistant prostate cancer (CRPC).
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news